Depression in women is more common during perimenopause (the transition to menopause) than at other times in the life cycle. Symptoms of depression may be different in perimenopausal women compared to younger or older women, and are often dismissed as part of normal menopause. This is an expert narrative review. There are several evidence-based screening modalities which can be integrated into routine women's health visits, and can facilitate distinguishing between depression and normal perimenopausal symptoms. There is emerging evidence regarding the effect of hormonal changes on the development of perimenopausal depression and its optimal treatment, though critical research gaps remain. Obstetrician-gynecologists and other primary care providers play a vital role in the detection and management of depression in women. Providers caring for women during perimenopause have a unique opportunity to diagnose depression in their patients and identify appropriate treatment options.
Introduction
Perimenopause is the interval in the menopausal transition including two years prior to the final menstrual period through one year of amenorrhea (Harlow et al. 2012) or can be described as Bthe transition to menopause^ (Gyllstrom et al. 2007 ). This period of life is associated with social transitions, as well as the emergence of physiological and psychological symptoms. Historically, this period in women's lives has been linked to depression and decreased quality of life. Involutional melancholia was listed as a syndrome in the Diagnostic and Statistical Manual of Mental Disorders, Second Edition (DSM-II) (Gyllstrom et al. 2007; Parry 2008) but was omitted from further editions based on findings at the time suggesting that there was no increased risk of depression during menopause (Weissman 1979) . More recent research, however, has confirmed that women are at greater risk of developing depression during perimenopause (Bromberger et al. 2011; Cohen et al. 2006; Mulhall et al. 2018) , and that depression during this phase is associated with hormonal changes, historical depressive episodes, life events (Rubinow 2003; Schmidt and Rubinow 2009) , and a genetic predisposition (Rozycka et al. 2016 ). As we identify new risk factors for depression during perimenopause, and as more women are entering the perimenopausal period each year (Raglan et al. 2014; Timur and Sahin 2010) , increased efforts are needed to understand women's healthcare providers' ability to recognize and manage depression.
Perimenopause is associated with physiological symptoms as well as overall declines in health, both of which contribute to decreased quality of life. Common physiological symptoms experienced by women during perimenopause include night sweats, hot flashes, and vulvovaginal atrophy, and more severe perimenopausal symptoms are associated with a greater negative impact on quality of life (Schneider 2002) . The perimenopausal period is also associated with increased risks of cardiovascular disease (Llaneza et al. 2012) , colon cancer, and osteoporosis (Mishra et al. 2003) . Along with these symptoms and conditions, perimenopause can lead to worsening of preexisting mental health disorders (Sajatovic et al. 2003) . Despite the impacts of perimenopause on women's overall quality of life, women's healthcare providers often focus on symptom reduction and overlook mental healthcare needs during this life transition.
While obstetrician-gynecologists (ob-gyns) have increasingly focused on mental healthcare in recent years, particularly as part of routine prenatal care (Accortt and Wong 2017) , there are multiple complex barriers to screening and incorporating mental healthcare into everyday practice (LaRocco-Cockburn et al. 2003 ). In addition, research into perimenopausal depression is ongoing and few data are available to practitioners about the risks and societal costs of depression during perimenopause and its optimal treatment. Symptom presentation and recommended treatment modalities may be different in perimenopausal women compared to women at other times of life (Bromberger et al. 2003; Clayton and Ninan 2010) . The purpose of this review is to outline evidence for the increased risk of depression during perimenopause, to discuss current knowledge regarding the screening and treatment of depression in perimenopausal women, and to identify critical research gaps in this area.
Depression during perimenopause: prevalence and diagnosis
The average age of menopause is 51 (Treloar 1981) , and studies of menopausal symptoms typically select participants between 45 and 55 years of age. Many women, however, begin experiencing menopausal symptoms significantly before or after this age range (Rubinow 2003) . It can be difficult to ascribe a Bstart date^to menopause, as amenorrhea or oligomenorrhea among women in this age group have many possible causes. High levels of follicle-stimulating hormone (FSH) with concurrent low plasma estradiol are suggestive of menopause, but do not always correlate with ongoing amenorrhea (Harlow et al. 2012; Rubinow 2003) . Symptoms of menopause are often present throughout the menopausal transition; therefore, in this review, we focus on the perimenopausal period from the year prior to the onset of amenorrhea from menopause through the first year of amenorrhea.
Older studies linking depression to perimenopause had inconsistent findings, due in part to the difficulties inherent in defining menopause, and also wide variability in methods for assessing depression. Yet, while most women move through the menopausal transition without experiencing depression, increasing evidence suggests that the perimenopausal period is a time of unique depression risk for women: over 40% of perimenopausal women experience symptoms of depression, though a much smaller percentage will seek care for these symptoms, receive a diagnosis of depression, or receive treatment (Timur and Sahin 2010) . Prospective longitudinal studies have been particularly informative to the field, following women from pre-to post-menopause and measuring multiple aspects of menopause onset. In one such study, investigators used the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID) to assess for major depression at baseline and throughout the study period while following participants' menstrual patterns. This study found that rates of depression were two to four times higher in women during perimenopause or early post-menopause than pre-menopause (Bromberger et al. 2011) . Other studies using the Center or Epidemiologic Studies Depression Scale (CES-D) had similar findings (Freeman et al. 2006a; Freeman et al. 2004 ).
While depression symptoms may emerge more frequently during the menopausal transition, several studies have concluded that the risk of experiencing these symptoms tends to decline in the postmenopausal period (Bromberger et al. 2011; Freeman et al. 2004) . Similarly, studies have shown declines in well-being during perimenopause, but improved well-being after sustained amenorrhea (Dennerstein et al. 2002) . Data are inconsistent, however, which may be related to differences in outcome measures or study populations (Matthews et al. 1990 ). Depression symptoms appear to increase during perimenopause; however, the prevalence of diagnosable depressive disorders may not be not higher during this period (Judd et al. 2012 ). Banger described this Baffective syndrome^as being important to study due to its negative impact on women's lives, despite the fact that it does not meet criteria for major depression (Banger 2002) .
Studies comparing the presentation of depression during perimenopause with that seen prior to perimenopause have found that symptom presentation may differ between these two periods of life. For instance, women experiencing depression during perimenopause may be more likely to experience irritability, nervousness, and frequent mood changes, but have fewer reports of generalized sadness compared to women prior to perimenopause (Bromberger et al. 2003) . Women may also present with more physiological symptoms of depression during perimenopause rather than a predominantly affectbased presentation , and these symptoms are often difficult to distinguish from normal menopausal symptoms. Higher levels of anger, fatigue, and sleep disturbance have been noted among perimenopausal women with depression (Gibbs et al. 2015) . Cognitive changes in perimenopausal women may also be associated with depression (Berent-Spillson et al. 2012 ).
Risk factors for developing perimenopausal depression

Hormonal changes
The established association between hormones and mood is one explanation for the increase in depression symptoms during perimenopause and other transition periods such as puberty and postpartum (Steiner et al. 2003) . Perimenopause is characterized by increased levels of the gonadotropins FSH and luteinizing hormone (LH), decreased estradiol and progesterone (ovarian steroids), and decreased adrenal androgen levels relative to premenopausal women (Rubinow 2003) . Several studies have linked these hormonal processes to the experience of mood symptoms in women during perimenopause (Soares 2017) . Women with rapidly rising levels of FSH, for instance, have been shown to be more likely to experience symptoms of depression during perimenopause (Freeman et al. 2004; Ryan et al. 2009 ), and decreased FSH levels are associated with reduced depression symptoms (Gordon et al. 2015) . Separately, high FSH and LH, as well as high variability in levels of FSH, LH, and estradiol, have been linked to increased prevalence of depression symptoms during perimenopause in women with no history of depression, even when adjusting for psychosocial and demographic factors (Freeman et al. 2006a) , and fluctuations in estradiol may also predict depressive symptoms, particularly among women with greater life stressors (Gordon et al. 2015) .
The effects of these hormonal fluctuations on mood may be directly related to the effects of estrogen on specific neural structures (Borrow and Cameron 2014; Schmidt 2005; Wharton et al. 2012) . A model of Bestradiol withdrawal^has been tested in at least one randomized trial , illustrating that the reduction in estradiol levels seen in perimenopause can lead to depression symptoms when experimentally modeled in humans (Harsh et al. 2009; Schmidt et al. 2015) . Declines in total serum estradiol have also been linked to depression during perimenopause (Ryan et al. 2009 ). Treatment with estradiol appears to reduce depression symptoms when administered in perimenopausal women (Schmidt 2005) .
Androgens are also associated with depression in the perimenopausal period. High relative levels of testosterone and low levels of dehydroepiandrosterone (DHEA) have both been linked to depression in perimenopause (Bromberger et al. 2010; Schmidt et al. 2002) . Administration of DHEA has been shown to reduce symptoms of depression in women during midlife (Schmidt et al. 2005) . Conversely, higher levels of dehydroepiandrosterone sulfate (DHEA-S), a sulfated metabolite of DHEA usually associated with healthy aging, have been linked to a reduction in depression symptoms in women with perimenopausal depression (Morrison et al. 2011) .
Despite these findings, other studies have failed to find associations between depressive symptoms and levels of reproductive hormones (Schmidt et al. 2004; Woods et al. 2007 ). Hormones may not be the exclusive driving factor behind the increased risk of depression during perimenopause, though shifts in certain hormone levels appear to contribute to increased vulnerability to depression. There are many other risk factors for depression symptoms such as overall well-being, social support, and other psychosocial mechanisms (Bromberger et al. 2010; Gibbs et al. 2013 ).
Previous depressive episodes
A history of depression is a risk factor for developing depression symptoms at any time in life, and perimenopause is no exception. Several studies have shown that women with a history of depression are more likely to develop depression during perimenopause Flores-Ramos et al. 2010) , and previous depressive episodes predict the occurrence of perimenopausal depression (Bromberger et al. 2011; Bromberger et al. 2010; Gibbs et al. 2013 ). Women who have experienced depression in the past are five times more likely to develop depression during perimenopause than women without a history of depression . This link suggests that, while hormonal changes may be important triggers for depression during perimenopause, a history of depression may be an important risk factor in the development of these symptoms (Gibbs et al. 2012) . One possible explanation is that individuals who are particularly vulnerable to hormone changes may elicit depression symptoms at multiple transition periods including perimenopause.
In addition, women who have experienced lifelong mental illness may find that their symptoms worsen during perimenopause. In a self-report study, women with a history of mental illness perceived worsened mental health symptoms during perimenopause (Sajatovic et al. 2003) . Symptoms of bipolar disorder have been shown to worsen during the perimenopausal transition, particularly the depressive symptoms of that disorder (Marsh et al. 2012 ).
Life events
Several studies have shown that women who experience major negative life events such as death of a spouse or child, or divorce, have an increased risk of developing depression during perimenopause . Negative life events are also linked to a decline in overall well-being during the perimenopausal transition (Smith-DiJulio et al. 2008 ). Gordon et al. found that negative life events predicted depressive symptoms during perimenopause, particularly when combined with estradiol variability (Gordon et al. 2016 ). This may indicate that vulnerability to depression during this life phase is complex, involving both a hormonal predisposition and triggering events in a woman's life (Gordon et al. 2015 (Gordon et al. , 2016 .
Somatic complaints
Vasomotor and somatic complaints such as hot flashes and vaginal dryness are common symptoms experienced by women during the perimenopause transition. These symptoms are reflective of reduced circulating estradiol and can lead to significant discomfort and distress, as well as negative effects on sexual relationships (Llaneza et al. 2012) . Hot flashes in particular have been linked to reduced sleep and difficulty participating in usual daily activities. Given the overlap in the effects of hot flashes and depression, several studies have closely examined whether hot flashes and other vasomotor symptoms may increase women's likelihood of experiencing depression symptoms. Cohen and colleagues found that women in perimenopause were more likely to experience depression symptoms if they also experienced hot flashes , while others have found that depressed perimenopausal women report more hot flashes than those without depression (de Kruif et al. 2016; Freeman et al. 2006a; Karaoulanis et al. 2012; Seritan et al. 2010 ). In addition, a greater number of vasomotor menopausal symptoms (e.g., vaginal dryness, hot flashes) among individual women have been associated with a higher likelihood of perimenopausal depression (Borkoles et al. 2015; Bromberger et al. 2015; Gallicchio et al. 2007) .
Despite these findings, some data indicate that the presence of hot flashes relates to the severity of depression symptoms, but may not increase the risk of depression diagnosis (Flores-Ramos et al. 2010) . Hot flashes and other vasomotor complaints may lead to increased reporting of depression symptoms or a heightened response to depression symptoms, rather than an increase in depression diagnosis. Several studies have failed to find a connection between vasomotor symptoms and perimenopausal depression (Becker et al. 2001; Steinberg et al. 2008) , and a recent review of the literature on the relationship between vasomotor complaints and depression during perimenopause concluded that the relationship between vasomotor complaints and depression in menopause is bidirectional (Natari et al. 2018) .
Vasomotor symptoms have also been tied to disrupted sleep patterns in perimenopausal women, which may contribute to the presence of depressive symptoms (Joffe et al. 2016 ). At least one study, however, has found that the relationship between sleep and depression is separate from the impact of vasomotor symptoms on sleep during the postmenopausal period, and that sleep onset and advanced sleep phase insomnia are important sleep features in women with insomnia (Vousoura et al. 2015) . This raises important questions about the impact of sleep during perimenopause. Perimenopausal women may also be at increased risk for sleep-disordered breathing (Galvan et al. 2017) , which can contribute to poor sleep and to depression (Wheaton et al. 2012 ).
Screening for depression in perimenopause: the role of the obstetrician-gynecologist
Similar to depression at other life stages, screening for depression during perimenopause often includes structured questionnaires such as the Beck Depression Inventory, Center of Epidemiologic Studies Depression Scale (CES-D), or the Primary Care Evaluation of Mental Disorders (PRIME-MD), along with interviews administered by a medical or mental health professionals. Some symptoms of perimenopause (e.g., sleeplessness) overlap with symptoms of depression. This may lead clinicians to overlook a depression diagnosis and regard symptoms as a normal part of the menopausal transition (Soares 2014) or conversely may lead to overdiagnosis of depression among women experiencing these symptoms.
With an aging patient population, the role of ob-gyns is increasingly moving away from the exclusive provision of reproductive care (Raglan et al. 2014) . Many women see their ob-gyns as the primary medical contact for routine and preventive medical care as well as non-gynecologic illnesses (Ehrenthal et al. 2011; Fink et al. 2001; Hale 1995; Henderson et al. 2002; Lewis et al. 2008; Scholle and Kelleher 2003; Weisman et al. 1995) . The American College of Obstetricians and Gynecologists (ACOG) recommends that ob-gyns use routine annual care visits as opportunities to screen for well woman and preventive care issues that may arise based on risk factors and age, including mental health issues (American College of and Gynecologists Committee on Gynecologic 2011). A majority of ob-gyns describe themselves as primary care providers despite their specialist training (Cassidy et al. 2003) . Despite this, ob-gyns may provide fewer mental health services (Williams et al. 1999 ) and less screening for medical conditions apart from the presenting concern (Cohen and Coco 2014) than other primary care providers (i.e., family practice and internal medicine providers).
Ob-gyns who do not consider themselves primary care providers are less likely to address mental or physical health concerns outside of the scope of their patients' presenting concerns (Schmidt et al. 1997) . Despite the fact that ob-gyns are often comfortable prescribing psychiatric medications to patients with mental health conditions such as anxiety and depression (Leddy et al. 2011) , they may not rely on accurate diagnostic tools when making the decision to prescribe (Fuller et al. 2013; Hill et al. 2005) . In fact, ob-gyns are less likely to use formal diagnostic criteria, assess for comorbidity (psychiatric or physical) with depression, make suicide assessments, and use the term Bdepression^when assessing for mental health (Williams et al. 1999) .
Because of the unique role of ob-gyns in the provision of women's healthcare, they are an important source of support and care for women with mental health concerns. Many obgyns, however, perceive that their training or experience in providing such care is inadequate, and may therefore avoid actively screening for these conditions (Cassidy et al. 2003; Kim et al. 2009; LaRocco-Cockburn et al. 2003) . Some studies have demonstrated that ob-gyns may not adequately recognize symptoms of mental illness (Cepoiu et al. 2008) .
Conversely, some ob-gyns may overestimate their abilities, leading to inaccurate diagnoses or the possibility of inappropriate treatment (Kim et al. 2009 ).
Patient factors may also influence the likelihood that obgyns are able to accurately assess for and treat mental health conditions such as depression. While women may feel comfortable with their ob-gyn, they may believe that he or she is not the appropriate source of treatment for such conditions (Bennett et al. 2009; Birndorf et al. 2001) and may not mention mental health symptoms unless prompted. Physicians' interviewing skills are crucial to ensuring that patients share concerns about mental health, and direct questioning may provide the best chance of recognizing the need for treatment when it exists. Appropriate training for ob-gyns in recognizing and treating depression is an important step toward functional improvement for patients (Bhat et al. 2017; Birndorf et al. 2001 ).
Treatment of perimenopausal depression
When treating women with depression during perimenopause, healthcare providers must give careful consideration to each patient's hormonal milieu and risk profile. No one treatment has been shown to be universally effective for treatment of perimenopausal depression, and recommendations should be personalized based on a patient's specific symptoms and risk profile.
Educating patients about depression and normalizing their experiences with these symptoms can be an important first step to reducing symptomatology (Epstein et al. 2010) . For many patients, however, additional treatment may be needed. Responses to various treatments are different in perimenopausal women with depression compared to those of women in other life stages (Dennerstein and Soares 2008) . Treatment of perimenopausal women often focuses on the reduction of physiological vasomotor symptoms in addition to the symptoms of psychological distress. Treatment studies have examined the impact of traditional antidepressant medications, as well as the use of hormone therapy (HT), in treating depression symptoms in perimenopausal depression. Additional studies have examined various alternative medications and techniques in alleviating symptoms. There are few randomized trials evaluating treatment modalities in women with perimenopausal depression, and more research is needed to determine what options are most effective in reducing symptoms and maximizing patient well-being (Frey 2009; Grigoriadis et al. 2003) .
Psychotherapy
Symptoms of depression have been shown to be effectively treated through collaborative care involving both psychotherapy and pharmacotherapy, suggesting that referral for psychotherapy should be part of treatment for women with depression during perimenopause (Hollon et al. 2014; Keller et al. 2000) . Studies of psychotherapy for treating depression during perimenopause have found positive outcomes, particularly those involving cognitive behavioral therapy and mindfulness techniques (Green et al. 2015) . Psychotherapy alone may be appropriate in women with less severe depression symptoms and may also be effective for improving vasomotor symptoms of perimenopause (McCurry et al. 2016) . In addition, psychotherapy may be vital for addressing psychosocial factors that could influence the experience of depression for perimenopausal women (Vivian-Taylor and Hickey 2014).
Hormone therapy
Findings from the Women's Health Initiative (WHI) have indicated that HT is associated with an increased incidence of breast cancer and cardiovascular disease (Rossouw et al. 2002) , which has led to decreased routine use of HT (Buist et al. 2004) . The decrease in HT prescriptions following the release of the WHI has been linked to an increase in prescriptions for antidepressants (McIntyre et al. 2005) . Ongoing studies will better quantify the risks and benefits for specific populations of women (Fischer et al. 2014; Riecher-Rossler and de Geyter 2007; Stuenkel et al. 2012) . Given that HT has been shown to be the most effective treatment for symptoms of perimenopause, most physicians currently offer HT to patients depending on individual circumstances and risk factors (Gleason et al. 2015; Lobo et al. 2006; Toffol et al. 2015) .
HT alone, and in conjunction with antidepressant medications, has been shown to be effective for the treatment of depression in the perimenopausal period (Frey 2009; Rubinow et al. 2015; Schmidt et al. 2000) . Women who are taking antidepressant medication can benefit from HT during the perimenopausal period, and the reduction in depression symptoms in those cases is associated with brain changes in the right frontal region (Morgan et al. 2007 ). Cessation of HT can be a risk factor for the development of depression symptoms , and depression symptoms previously controlled by HT may re-emerge after a patient stops taking it (Citarella et al. 2013; McIntyre et al. 2005) . Recent studies have also shown that lifelong estradiol exposure through, for instance, oral contraceptives can reduce risks of developing depression during perimenopause, and that hormone replacement therapy during the menopausal transition may play a role in reducing the onset of depression symptoms (Gordon et al. 2018; Marsh et al. 2017 ).
Antidepressants
Antidepressant medications, particularly selective serotonin reuptake inhibitors (SSRIs), are effective in treating depression during perimenopause, either alone or combined with HT (Freeman et al. 2006b; Macias-Cortes Edel et al. 2015) . Some experts recommend that SSRIs should be used as first-line treatment for women with perimenopausal depression (Gyllstrom et al. 2007) . In some studies, SSRIs are superior to HT in reducing depression symptoms, as well as in improving other menopausal symptoms (Freeman et al. 2013; Soares et al. 2006) . SSRIs may be effective in improving cognitive symptoms along with depression (Wroolie et al. 2006) . Despite this, women in older age groups, including those in the perimenopausal transition, may be less responsive to SSRI treatment than younger women (Grigoriadis et al. 2003) . Therefore, SSRIs may be more effective when combined with HT in this patient population (Graziottin and Serafini 2009 ). Risks of SSRIs may include bone loss (Rauma et al. 2016 ) and fracture risk (Sheu et al. 2015) , which could be of particular concern to older women, and baseline osteoporosis risk must be taken into account (Rauma et al. 2016) .
Another class of antidepressant medications, serotoninnorepinephrine reuptake inhibitors (SNRIs), may alleviate depression symptoms, as well as co-occurring menopausal symptoms, without the need for adjunctive HT (Joffe et al. 2007; Kornstein et al. 2015; Parry 2010) . SNRIs have been shown to reduce vasomotor symptoms (Archer et al. 2009 ); however, they have not demonstrated significantly improved outcomes in treating perimenopausal depression when directly compared to SSRIs (Soares et al. 2010) .
Alternative medicine
There are many proponents of alternative or complementary treatments for depression symptoms during perimenopause, including relaxation, acupuncture, exercise, diet changes, and herbal supplements, but there is limited research supporting the effectiveness of these options. Some studies have indicated that St. John's wort has efficacy in treating mild to moderate depression in women generally (Deligiannidis and Freeman 2010) , and perimenopausal women, particularly when combined with black cohosh (Briese et al. 2007) . St. John's wort has also been shown to reduce vasomotor symptoms of menopause (Al-Akoum et al. 2009 ). A prescribed formulation of Chinese herbs called GengNianLe showed no significant improvement versus a control group when studied for effects on perimenopausal depression (Qu et al. 2009 ), but specialized homeopathic treatments may be helpful in reducing both depression and vasomotor symptoms (Macias-Cortes Edel et al. 2015) .
Exercise may reduce symptoms of depression during perimenopause while increasing overall well-being (Elavsky and McAuley 2007) . One study demonstrated that low-intensity movement such as daily stretching may decrease depressive symptoms in perimenopausal women (Kai et al. 2016) . While some studies of alternative treatments have shown promising findings, the results are generally mixed (Parry 2010) . This is made more challenging by variability in dosing recommendations for certain herbal interventions and a lack of replicated studies. Additionally, varying severity of depression symptoms mean that certain presentations, particularly those suggestive of severe depression, would be better managed by psychiatric or psychotherapeutic treatment. Future research is needed to identify effective alternative treatments for perimenopausal depression.
Conclusions
Depression is a treatable medical condition, and increased mental health screening by primary care providers including ob-gyns is critical for improving patient outcomes. Routine standardized screening ensures that patients with depression receive the diagnosis and care that they need . Improving ob-gyn training related to depression screening and appropriate management would have a significant positive impact on patient well-being and recovery. This is particularly true for depression during the perimenopausal period, when physicians may not be aware of the increased risk during this life stage and dismiss symptoms as normal. Training must focus on the diagnosis and treatment of depression, and highlight risk factors and symptom profiles that are unique to women in perimenopause. This will be particularly important for ob-gyns as the patient population in the USA ages, and a greater proportion of patients fall within the perimenopausal lifestage.
Ob-gyns are often the primary point-of-care for women, and further research is needed to determine how they screen and treat patients presenting with depression symptoms during perimenopause, particularly given the lack of standardized recommendations. This information is important for understanding access to care for perimenopausal women, and for determining whether they are receiving the care that they need. A better understanding of how ob-gyns recognize and manage patients whose depression severity is outside their scope of care could also provide valuable information for referral networks. In this way, ob-gyns could fulfill an important role for perimenopausal women not just as primary caregivers, but as access points to further psychiatric care.
Depression during perimenopause has important impacts on quality of life and overall well-being. Despite this, rates of routine screening for depression during perimenopause are unknown, and physician beliefs and knowledge about symptoms of depression in perimenopause have not been investigated. Gaining increased insight into ob-gyns' knowledge and practice patterns could lead to the identification of barriers to women receiving care, as well as methods for improving mental healthcare for women during perimenopause. Given that depression responds to treatment in many cases, increasing screening and awareness about this disorder's prevalence during perimenopause could help to reduce the overall disease burden of perimenopausal depression and improve quality of life during the perimenopausal transition.
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